CLINICAL TRIALS PROFILE FOR CESAMET
✉ Email this page to a colleague
All Clinical Trials for Cesamet
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00272207 ↗ | A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia | Completed | Valeant Canada Limited | Phase 2 | 2006-04-01 | The purpose of the study is to determine whether or not the drug Nabilone significantly reduces pain and improves quality of life in patients with fibromyalgia. |
| NCT00272207 ↗ | A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia | Completed | Winnipeg Regional Health Authority | Phase 2 | 2006-04-01 | The purpose of the study is to determine whether or not the drug Nabilone significantly reduces pain and improves quality of life in patients with fibromyalgia. |
| NCT00380913 ↗ | Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy | Completed | NEMA Research, Inc. | Phase 4 | 2006-09-01 | This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to diabetic peripheral neuropathy. |
| NCT00380965 ↗ | Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy | Completed | NEMA Research, Inc. | Phase 4 | 2006-10-01 | This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to chemotherapy-induced neuropathic pain in patients with cancer. |
| NCT00381264 ↗ | Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis | Completed | NEMA Research, Inc. | Phase 4 | 2006-09-01 | This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to Multiple Sclerosis. |
| NCT00384410 ↗ | Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients | Unknown status | Bausch Health Americas, Inc. | Phase 2 | 2005-12-01 | Sleep disturbance is perhaps one of the most prevalent complaints of patients with long-standing painful conditions. Nabilone is a medication that is approved by Health Canada as an anti-emetic (prevent vomiting) for patients undergoing chemotherapy. Nabilone, due to its sleep promoting properties, is sometimes prescribed by physicians to pain patients to help improve their sleep. However, there is no direct research evidence to either support or refute this practice. This study will investigate if nabilone is effective in improving sleep in insomnia and pain patients. |
| NCT00384410 ↗ | Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients | Unknown status | Valeant Pharmaceuticals International, Inc. | Phase 2 | 2005-12-01 | Sleep disturbance is perhaps one of the most prevalent complaints of patients with long-standing painful conditions. Nabilone is a medication that is approved by Health Canada as an anti-emetic (prevent vomiting) for patients undergoing chemotherapy. Nabilone, due to its sleep promoting properties, is sometimes prescribed by physicians to pain patients to help improve their sleep. However, there is no direct research evidence to either support or refute this practice. This study will investigate if nabilone is effective in improving sleep in insomnia and pain patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Cesamet
Condition Name
Clinical Trial Locations for Cesamet
Trials by Country
Clinical Trial Progress for Cesamet
Clinical Trial Phase
Clinical Trial Sponsors for Cesamet
Sponsor Name
